Cargando…

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy

Heart failure (HF) is a growing major public health and economic concern in the United States and worldwide. Heart failure mortality rates can be as high as 75% despite advances in therapies. HF is expected to be the fastest growing among all cardiovascular diseases, with HF-associated direct medica...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldhaeefi, Mohammed, Beers, Brandon, Shah, Jenny, Rizi, Saba Saeidi, Rungkitwattanakul, Dhakrit, Nimoh, Oliver, Frimpong, Victoria, Gonzalez, Jackie, Belrhiti, Sanaa, Urooj, Fatima, Williams, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037629/
https://www.ncbi.nlm.nih.gov/pubmed/36961036
http://dx.doi.org/10.3390/pharmacy11020058
_version_ 1784911925536096256
author Aldhaeefi, Mohammed
Beers, Brandon
Shah, Jenny
Rizi, Saba Saeidi
Rungkitwattanakul, Dhakrit
Nimoh, Oliver
Frimpong, Victoria
Gonzalez, Jackie
Belrhiti, Sanaa
Urooj, Fatima
Williams, Deborah
author_facet Aldhaeefi, Mohammed
Beers, Brandon
Shah, Jenny
Rizi, Saba Saeidi
Rungkitwattanakul, Dhakrit
Nimoh, Oliver
Frimpong, Victoria
Gonzalez, Jackie
Belrhiti, Sanaa
Urooj, Fatima
Williams, Deborah
author_sort Aldhaeefi, Mohammed
collection PubMed
description Heart failure (HF) is a growing major public health and economic concern in the United States and worldwide. Heart failure mortality rates can be as high as 75% despite advances in therapies. HF is expected to be the fastest growing among all cardiovascular diseases, with HF-associated direct medical costs projected to nearly double over the next 10 years. Hospital admissions, re-admission, and medical cost are a huge burden to the healthcare system, and this is estimated to have increased gradually over the past decades despite the available advances in HF treatment and prevention. Many heart failure therapies have shown improvement in terms of mortality, morbidity, and symptomatic management. Guideline-directed medical therapy (GDMT) for heart failure has proven its ability to reduce morbidity and mortality by 66%. GDMT is recommended to be used among all HF patients when appropriate. In recent years, two new drug classes, angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, were approved by the United States Food and Drug Administration (US FDA) for the management of heart failure. The exact mechanism by which the SGLT-2 inhibitors attenuate the inflammatory process remains unclear. Several mechanisms have been suggested related to the cardiovascular benefit of SGLT-2 inhibitors, including a reduction in inflammation, improvement in natriuresis/diuresis, and promotion of the use of ketones as a secondary energy source. Clinical data showed that SGLT-2 inhibitors have morbidity and mortality benefits within 30 days of initiation. Studies have proven that clinical pharmacists practicing in HF inpatient and outpatient settings resulted in a reduction of HF hospitalization and an increase in the uptake of GDMT by initiating or up-titrating GDMT agents as well as providing patient education.
format Online
Article
Text
id pubmed-10037629
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100376292023-03-25 Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy Aldhaeefi, Mohammed Beers, Brandon Shah, Jenny Rizi, Saba Saeidi Rungkitwattanakul, Dhakrit Nimoh, Oliver Frimpong, Victoria Gonzalez, Jackie Belrhiti, Sanaa Urooj, Fatima Williams, Deborah Pharmacy (Basel) Review Heart failure (HF) is a growing major public health and economic concern in the United States and worldwide. Heart failure mortality rates can be as high as 75% despite advances in therapies. HF is expected to be the fastest growing among all cardiovascular diseases, with HF-associated direct medical costs projected to nearly double over the next 10 years. Hospital admissions, re-admission, and medical cost are a huge burden to the healthcare system, and this is estimated to have increased gradually over the past decades despite the available advances in HF treatment and prevention. Many heart failure therapies have shown improvement in terms of mortality, morbidity, and symptomatic management. Guideline-directed medical therapy (GDMT) for heart failure has proven its ability to reduce morbidity and mortality by 66%. GDMT is recommended to be used among all HF patients when appropriate. In recent years, two new drug classes, angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, were approved by the United States Food and Drug Administration (US FDA) for the management of heart failure. The exact mechanism by which the SGLT-2 inhibitors attenuate the inflammatory process remains unclear. Several mechanisms have been suggested related to the cardiovascular benefit of SGLT-2 inhibitors, including a reduction in inflammation, improvement in natriuresis/diuresis, and promotion of the use of ketones as a secondary energy source. Clinical data showed that SGLT-2 inhibitors have morbidity and mortality benefits within 30 days of initiation. Studies have proven that clinical pharmacists practicing in HF inpatient and outpatient settings resulted in a reduction of HF hospitalization and an increase in the uptake of GDMT by initiating or up-titrating GDMT agents as well as providing patient education. MDPI 2023-03-17 /pmc/articles/PMC10037629/ /pubmed/36961036 http://dx.doi.org/10.3390/pharmacy11020058 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Aldhaeefi, Mohammed
Beers, Brandon
Shah, Jenny
Rizi, Saba Saeidi
Rungkitwattanakul, Dhakrit
Nimoh, Oliver
Frimpong, Victoria
Gonzalez, Jackie
Belrhiti, Sanaa
Urooj, Fatima
Williams, Deborah
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
title Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
title_full Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
title_fullStr Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
title_full_unstemmed Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
title_short Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
title_sort sodium-glucose cotransporter-2 (sglt-2) inhibitors use among heart failure patients and the role of pharmacists in early initiation of therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037629/
https://www.ncbi.nlm.nih.gov/pubmed/36961036
http://dx.doi.org/10.3390/pharmacy11020058
work_keys_str_mv AT aldhaeefimohammed sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT beersbrandon sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT shahjenny sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT rizisabasaeidi sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT rungkitwattanakuldhakrit sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT nimoholiver sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT frimpongvictoria sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT gonzalezjackie sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT belrhitisanaa sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT uroojfatima sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy
AT williamsdeborah sodiumglucosecotransporter2sglt2inhibitorsuseamongheartfailurepatientsandtheroleofpharmacistsinearlyinitiationoftherapy